MedPath

FDA Sets PDUFA Date for Gene Therapy Targeting AADC Deficiency

• The FDA has set an action date of April 29, 2025, for a Biologics License Application (BLA) for a gene therapy intended to treat Aromatic L-Amino Acid Decarboxylase (AADC) deficiency. • The gene therapy, already approved in the UK and European Union under the brand name Upstaza since 2022, showed promising results in clinical trials. • The pivotal phase 1b/2 FELIX clinical trial (NCT04404660) demonstrated good rates of overall complete remission and median duration of remission for a CAR-T therapy.

The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) action date of April 29, 2025, for a Biologics License Application (BLA) concerning a gene therapy designed to treat Aromatic L-Amino Acid Decarboxylase (AADC) deficiency. This regulatory milestone marks a significant step toward potential approval in the United States for a therapy already available in other regions.
The gene therapy has been approved in the UK and European Union since 2022 under the brand name Upstaza. The therapy targets the underlying genetic defect in AADC deficiency, a rare and severe neurological disorder that affects the production of dopamine and serotonin.
CAR-T therapy was approved based on the pivotal phase 1b/2 FELIX clinical trial (NCT04404660), which showed good rates of overall complete remission and median duration of remission. The safety data set for the trial included 39 patients who were treated with ALLO-316.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CAR-T Therapy Shows Promise in Lenalidomide-Refractory Multiple Myeloma

CARTITUDE-4 trial results show promise for patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy, indicating a potential new treatment option.
Five-year follow-up data from the TRANSCEND-NHL-001 trial were discussed, providing insights into the long-term efficacy and safety of CAR-T cell therapy in lymphoma.

Advancements in Gene and Cell Therapies Target Diverse Diseases

Ultragenyx seeks accelerated FDA approval for UX111, a gene therapy for MPSIII, based on Phase 1/2/3 trial data.
Arbor Biotechnologies' CRISPR-based therapy ABO-101 receives clearance for US trial in Primary Hyperoxaluria Type 1.

FDA Clears First IND for Circular RNA Therapy, RiboX

RiboX receives FDA clearance for its Investigational New Drug (IND) application, marking the first such clearance for a circular RNA therapy.
A study co-authored by a physician at the Cancer Center at Children's Hospital of Philadelphia was recently published in Blood, adding to the advancements in gene and cell therapies.

Liso-cel Demonstrates Significant Response in Relapsed/Refractory Marginal Zone Lymphoma

Bristol Myers Squibb's liso-cel achieved a statistically significant and clinically meaningful overall response rate in patients with relapsed or refractory marginal zone lymphoma.
The Phase 2 trial results highlight the potential of liso-cel as an effective treatment option for this challenging patient population.

Gene Therapy for Parkinson's Shows Promise in Phase 2 Trial

A phase 2 trial of a gene therapy for Parkinson's disease demonstrated an average improvement of 18 points in UPDRS Part 3 "off" medication score at 26 weeks post-treatment.
The data comes from a phase 2 substudy (NCT03999801) that treated the fellow eyes of patients who had previously been treated with ABBV-RGX-314.

Benitec BioPharma's Gene Therapy Shows Promising Results in Oculopharyngeal Muscular Dystrophy Trial

Benitec BioPharma reports a 35% reduction in total score on the Sydney Swallow Questionnaire in the first patient treated with their gene therapy for oculopharyngeal muscular dystrophy (OPMD).
Therapeutic RNA editing has been clinically demonstrated in humans for the first time, according to the company's press release.

CAR-T Therapy Demonstrates Significant Reduction in Multiple Myeloma Disease Burden

Data from the CARTITUDE-4 clinical trial indicates that CAR-T therapy shows improved outcomes compared to standard of care for multiple myeloma patients.
Cerebrospinal fluid (CSF) analyses from patients treated with a novel therapy showed over 80% reduction in NAA levels from baseline, suggesting significant therapeutic impact.

Gene and Cell Therapy Data Roundup: Updates in DLBCL, SMA, XLRP, and More

REGENXBIO's RGX-121 shows sustained efficacy in MPSII, with significant reduction in heparan sulfate levels and reduced need for enzyme replacement therapy.
Biogen's nusinersen demonstrates superior efficacy in SMA at a higher dose compared to the FDA-approved dose, showing statistically significant improvement in CHOP-INTEND scores.

Cell Therapy Shows Promise in Progressive Multiple Sclerosis

A cell therapy is under development for progressive multiple sclerosis (MS) patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.
GT201, a novel therapy, previously received IND clearance from China’s Center for Drug Evaluation in July 2023, marking a significant regulatory milestone.

Galapagos' ATALANTA-1 Clinical Trial for Hemophilia A to Expand to the US Following IND Clearance

Galapagos' ATALANTA-1 phase 1/2 clinical trial (NCT06561425) for hemophilia A is set to expand to the United States after receiving IND clearance.
The ATALANTA-1 trial is already ongoing in Europe and will now include US sites to further evaluate the safety and efficacy of their hemophilia A treatment.

Reference News

[1]
CGTLive®'s Weekly Rewind – November 15, 2024
cgtlive.com · Nov 16, 2024

Weekly highlights include CAR-T therapy approval, Chris Wright discussing ASGCT 2024, gene therapy Upstaza approved in U...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy